Then the combination of BRAF inhibitor and MEK inhibitor (always consists of dabrafenib and trametinib) rapidly became the standard targeted treatment for BRAFV600E mutation‐positive melanoma.20.Aside from these, the immune checkpoint inhibition approach has also gained unprecedented progress for melanoma management and even leads the way for other malignancies 21, 22, 23. This evidence concerns the gene BRAF and melanoma.